StockData
Veracyte, Inc. logo

Veracyte, Inc. (VCYT) income statement

VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3029% below fair value
$25.04−0.53 (-2.07%)

Close on Nov 19, 2026Market cap $2.01BP/E 17.9Yield –

Veracyte, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
71.7%
Operating margin
18.8%
Net margin
20.4%
Return on equity, FY2025
5.3%

Financial strength

Current ratio
9.16
Debt to equity
–
Debt to assets
–
Cash to current liabilities
477.4%

Valuation

P/E ratio
17.9
Price to sales
3.58
Price to book
1.45
Dividend yield
–

See a number that looks wrong?